NICE publishes second appraisal consultation document for Zytiga

NICE

26 January 2021 - NICE has had another look at abiraterone acetate for the treatment of patients with newly diagnosed high-risk hormone sensitive metastatic prostate cancer.

Abiraterone acetate, when used in combination with prednisone or prednisolone plus androgen deprivation therapy, is not recommended, within its marketing authorisation, for the treatment of patients with newly diagnosed high-risk hormone-sensitive metastatic prostate cancer.

Janssen has proposed a commercial arrangement that would make abiraterone acetate available to the NHS at a discount. Even accounting for this, the cost effectiveness estimates of the abiraterone acetate combination compared with either androgen deprivation therapy alone or docetaxel and androgen deprivation therapy for the whole population are higher than the range normally considered a cost effective use of NHS resources. There are no appropriate cost effectiveness estimates for when docetaxel cannot be used or is unsuitable.

Read NICE Appraisal Consultation Document for abiraterone acetate

Michael Wonder

Posted by:

Michael Wonder